The Association of Clinical Research Organizations (ACRO) has elected William Sharbaugh, CEO of PPD, as chair for 2010. Sharbaugh joined PPD in 2007 after spending more than 16 years in the pharma industry at companies including Bristol-Myers Squibb and Merck & Co.
Joe Herring, chairman and CEO of Covance, has been chose as chair-elect. Herring joined Covance in 1996 and before this held positions at Baxter and Caremark International.
In addition, Icon has become a regular member of ACRO, with John Hubbard, global president of Icon clinical research, taking a seat on the Association’s board.
MDS Inc has named Steve West as its CEO. West was president of MDS Nordion and chief operating officer of MDS Inc and will now replace Stephen DeFalco as CEO.
Furthermore, Peter Dans has been promoted from senior vice president (SVP), finance at MDS Inc to become chief financial officer (CFO). Dans replaces Doug Prince as CFO.
Prince is expected to leave MDS in March. Over the next three months he will work to achieve a smooth transition and support MDS’ repositioning actions, including the proposed sale of the Pharma Services business.
Brian Kelly has been named as group president of i3 Innovus, i3 Drug Safety and i3 Pharma Informatics. Kelly was general manager of Covance’s central laboratory services and also spent nine years at Merck & Co.
i3 has also appointed Tracy Ken Tsuetaki as president of its research division and Andrew Chong as regional VP for Asia-Pacific. Tsuetaki joins i3 from Covance and has also worked at Catalent Pharma Solutions, Quintiles and Laureate Pharma.
Chong’s appointment emphasises i3’s commitment to Asia-Pacific. He has 20 years experience in the industry, most recently at Genentech.
Prologue has appointed Art Ziegler as VP of business development. Ziegler has 25 years of clinical research and business development experience at companies including Premier Research and Johnson & Johnson.